glycoprotein	verapamil	69	68	false	none	R-verapamil is 94% bound to plasma albumin, while S-verapamil is 88% bound.  In addition, R-verapamil is 92% and S-verapamil 86% bound to alpha-1 acid glycoprotein.  		none	11170	none	11170
glycoprotein	verapamil	69	68	false	none	R-verapamil is 94% bound to plasma albumin, while S-verapamil is 88% bound.  In addition, R-verapamil is 92% and S-verapamil 86% bound to alpha-1 acid glycoprotein.  		none	11170	none	11170
glycoprotein	verapamil	69	69	false	none	In addition, R-verapamil is 92% and S-verapamil 86% bound to alpha-1 acid glycoprotein.  		none	11170	none	11170
glycoprotein	verapamil	69	69	false	none	In addition, R-verapamil is 92% and S-verapamil 86% bound to alpha-1 acid glycoprotein.  		none	11170	none	11170
glycoprotein	verapamil	69	70	true	positive	In addition, R-verapamil is 92% and S-verapamil 86% bound to alpha-1 acid glycoprotein.  In patients with hepatic insufficiency, metabolism of immediate-release verapamil is delayed and elimination half-life prolonged up to 14 to 16 hours because of the extensive hepatic metabolism [see Use in Specific Populations (8.6)].  		none	11170	none	11170
glycoprotein	verapamil	69	70	true	positive	In addition, R-verapamil is 92% and S-verapamil 86% bound to alpha-1 acid glycoprotein.  In patients with hepatic insufficiency, metabolism of immediate-release verapamil is delayed and elimination half-life prolonged up to 14 to 16 hours because of the extensive hepatic metabolism [see Use in Specific Populations (8.6)].  		none	11170	none	11170
glycoprotein	verapamil	69	71	true	positive	In addition, R-verapamil is 92% and S-verapamil 86% bound to alpha-1 acid glycoprotein.  In patients with hepatic insufficiency, metabolism of immediate-release verapamil is delayed and elimination half-life prolonged up to 14 to 16 hours because of the extensive hepatic metabolism [see Use in Specific Populations (8.6)].  In addition, in these patients there is a reduced first pass effect, and verapamil is more bioavailable.  		none	11170	none	11170
glycoprotein	verapamil	69	71	true	positive	In addition, R-verapamil is 92% and S-verapamil 86% bound to alpha-1 acid glycoprotein.  In patients with hepatic insufficiency, metabolism of immediate-release verapamil is delayed and elimination half-life prolonged up to 14 to 16 hours because of the extensive hepatic metabolism [see Use in Specific Populations (8.6)].  In addition, in these patients there is a reduced first pass effect, and verapamil is more bioavailable.  		none	11170	none	11170
glycoprotein	Verapamil	69	68	false	none	R-verapamil is 94% bound to plasma albumin, while S-verapamil is 88% bound.  In addition, R-verapamil is 92% and S-verapamil 86% bound to alpha-1 acid glycoprotein.  		none	11170	none	11170
glycoprotein	Verapamil	69	68	false	none	R-verapamil is 94% bound to plasma albumin, while S-verapamil is 88% bound.  In addition, R-verapamil is 92% and S-verapamil 86% bound to alpha-1 acid glycoprotein.  		none	11170	none	11170
glycoprotein	Verapamil	69	69	false	none	In addition, R-verapamil is 92% and S-verapamil 86% bound to alpha-1 acid glycoprotein.  		none	11170	none	11170
glycoprotein	Verapamil	69	69	false	none	In addition, R-verapamil is 92% and S-verapamil 86% bound to alpha-1 acid glycoprotein.  		none	11170	none	11170
glycoprotein	Verapamil	69	70	true	positive	In addition, R-verapamil is 92% and S-verapamil 86% bound to alpha-1 acid glycoprotein.  In patients with hepatic insufficiency, metabolism of immediate-release verapamil is delayed and elimination half-life prolonged up to 14 to 16 hours because of the extensive hepatic metabolism [see Use in Specific Populations (8.6)].  		none	11170	none	11170
glycoprotein	Verapamil	69	70	true	positive	In addition, R-verapamil is 92% and S-verapamil 86% bound to alpha-1 acid glycoprotein.  In patients with hepatic insufficiency, metabolism of immediate-release verapamil is delayed and elimination half-life prolonged up to 14 to 16 hours because of the extensive hepatic metabolism [see Use in Specific Populations (8.6)].  		none	11170	none	11170
glycoprotein	Verapamil	69	71	true	positive	In addition, R-verapamil is 92% and S-verapamil 86% bound to alpha-1 acid glycoprotein.  In patients with hepatic insufficiency, metabolism of immediate-release verapamil is delayed and elimination half-life prolonged up to 14 to 16 hours because of the extensive hepatic metabolism [see Use in Specific Populations (8.6)].  In addition, in these patients there is a reduced first pass effect, and verapamil is more bioavailable.  		none	11170	none	11170
glycoprotein	Verapamil	69	71	true	positive	In addition, R-verapamil is 92% and S-verapamil 86% bound to alpha-1 acid glycoprotein.  In patients with hepatic insufficiency, metabolism of immediate-release verapamil is delayed and elimination half-life prolonged up to 14 to 16 hours because of the extensive hepatic metabolism [see Use in Specific Populations (8.6)].  In addition, in these patients there is a reduced first pass effect, and verapamil is more bioavailable.  		none	11170	none	11170
procaine	basis	23	23	false	none	Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  		8701	0	8701	1046801
procaine	basis	23	23	false	none	Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  		8701	0	8701	1046801
procaine	verapamil	23	21	true	positive	Verapamil may shorten the antegrade effective refractory period of the accessory bypass tract.  Acceleration of ventricular rate and/or ventricular fibrillation has been reported in patients with atrial flutter or atrial fibrillation and a coexisting accessory AV pathway following administration of verapamil [see Warnings and Precautions (5.4)].  Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  		8701	11170	8701	11170
procaine	verapamil	23	21	true	positive	Verapamil may shorten the antegrade effective refractory period of the accessory bypass tract.  Acceleration of ventricular rate and/or ventricular fibrillation has been reported in patients with atrial flutter or atrial fibrillation and a coexisting accessory AV pathway following administration of verapamil [see Warnings and Precautions (5.4)].  Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  		8701	11170	8701	11170
procaine	verapamil	23	23	true	positive	Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  		8701	11170	8701	11170
procaine	verapamil	23	23	true	positive	Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  		8701	11170	8701	11170
procaine	verapamil	23	22	true	positive	Acceleration of ventricular rate and/or ventricular fibrillation has been reported in patients with atrial flutter or atrial fibrillation and a coexisting accessory AV pathway following administration of verapamil [see Warnings and Precautions (5.4)].  Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  		8701	11170	8701	11170
procaine	verapamil	23	22	true	positive	Acceleration of ventricular rate and/or ventricular fibrillation has been reported in patients with atrial flutter or atrial fibrillation and a coexisting accessory AV pathway following administration of verapamil [see Warnings and Precautions (5.4)].  Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  		8701	11170	8701	11170
procaine	verapamil	23	25	true	positive	Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  It is not known whether this action is important at the doses used in man.  Hemodynamics    Verapamil reduces afterload and myocardial contractility.  		8701	11170	8701	11170
procaine	verapamil	23	25	true	positive	Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  It is not known whether this action is important at the doses used in man.  Hemodynamics    Verapamil reduces afterload and myocardial contractility.  		8701	11170	8701	11170
procaine	Verapamil	23	21	true	positive	Verapamil may shorten the antegrade effective refractory period of the accessory bypass tract.  Acceleration of ventricular rate and/or ventricular fibrillation has been reported in patients with atrial flutter or atrial fibrillation and a coexisting accessory AV pathway following administration of verapamil [see Warnings and Precautions (5.4)].  Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  		8701	11170	8701	11170
procaine	Verapamil	23	21	true	positive	Verapamil may shorten the antegrade effective refractory period of the accessory bypass tract.  Acceleration of ventricular rate and/or ventricular fibrillation has been reported in patients with atrial flutter or atrial fibrillation and a coexisting accessory AV pathway following administration of verapamil [see Warnings and Precautions (5.4)].  Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  		8701	11170	8701	11170
procaine	Verapamil	23	23	true	positive	Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  		8701	11170	8701	11170
procaine	Verapamil	23	23	true	positive	Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  		8701	11170	8701	11170
procaine	Verapamil	23	22	true	positive	Acceleration of ventricular rate and/or ventricular fibrillation has been reported in patients with atrial flutter or atrial fibrillation and a coexisting accessory AV pathway following administration of verapamil [see Warnings and Precautions (5.4)].  Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  		8701	11170	8701	11170
procaine	Verapamil	23	22	true	positive	Acceleration of ventricular rate and/or ventricular fibrillation has been reported in patients with atrial flutter or atrial fibrillation and a coexisting accessory AV pathway following administration of verapamil [see Warnings and Precautions (5.4)].  Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  		8701	11170	8701	11170
procaine	Verapamil	23	25	true	positive	Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  It is not known whether this action is important at the doses used in man.  Hemodynamics    Verapamil reduces afterload and myocardial contractility.  		8701	11170	8701	11170
procaine	Verapamil	23	25	true	positive	Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  It is not known whether this action is important at the doses used in man.  Hemodynamics    Verapamil reduces afterload and myocardial contractility.  		8701	11170	8701	11170
basis	verapamil	23	21	true	positive	Verapamil may shorten the antegrade effective refractory period of the accessory bypass tract.  Acceleration of ventricular rate and/or ventricular fibrillation has been reported in patients with atrial flutter or atrial fibrillation and a coexisting accessory AV pathway following administration of verapamil [see Warnings and Precautions (5.4)].  Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  		0	11170	1046801	11170
basis	verapamil	23	21	true	positive	Verapamil may shorten the antegrade effective refractory period of the accessory bypass tract.  Acceleration of ventricular rate and/or ventricular fibrillation has been reported in patients with atrial flutter or atrial fibrillation and a coexisting accessory AV pathway following administration of verapamil [see Warnings and Precautions (5.4)].  Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  		0	11170	1046801	11170
basis	verapamil	23	23	true	positive	Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  		0	11170	1046801	11170
basis	verapamil	23	23	true	positive	Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  		0	11170	1046801	11170
basis	verapamil	23	22	true	positive	Acceleration of ventricular rate and/or ventricular fibrillation has been reported in patients with atrial flutter or atrial fibrillation and a coexisting accessory AV pathway following administration of verapamil [see Warnings and Precautions (5.4)].  Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  		0	11170	1046801	11170
basis	verapamil	23	22	true	positive	Acceleration of ventricular rate and/or ventricular fibrillation has been reported in patients with atrial flutter or atrial fibrillation and a coexisting accessory AV pathway following administration of verapamil [see Warnings and Precautions (5.4)].  Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  		0	11170	1046801	11170
basis	verapamil	23	25	true	positive	Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  It is not known whether this action is important at the doses used in man.  Hemodynamics    Verapamil reduces afterload and myocardial contractility.  		0	11170	1046801	11170
basis	verapamil	23	25	true	positive	Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  It is not known whether this action is important at the doses used in man.  Hemodynamics    Verapamil reduces afterload and myocardial contractility.  		0	11170	1046801	11170
basis	Verapamil	23	21	true	positive	Verapamil may shorten the antegrade effective refractory period of the accessory bypass tract.  Acceleration of ventricular rate and/or ventricular fibrillation has been reported in patients with atrial flutter or atrial fibrillation and a coexisting accessory AV pathway following administration of verapamil [see Warnings and Precautions (5.4)].  Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  		0	11170	1046801	11170
basis	Verapamil	23	21	true	positive	Verapamil may shorten the antegrade effective refractory period of the accessory bypass tract.  Acceleration of ventricular rate and/or ventricular fibrillation has been reported in patients with atrial flutter or atrial fibrillation and a coexisting accessory AV pathway following administration of verapamil [see Warnings and Precautions (5.4)].  Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  		0	11170	1046801	11170
basis	Verapamil	23	23	true	positive	Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  		0	11170	1046801	11170
basis	Verapamil	23	23	true	positive	Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  		0	11170	1046801	11170
basis	Verapamil	23	22	true	positive	Acceleration of ventricular rate and/or ventricular fibrillation has been reported in patients with atrial flutter or atrial fibrillation and a coexisting accessory AV pathway following administration of verapamil [see Warnings and Precautions (5.4)].  Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  		0	11170	1046801	11170
basis	Verapamil	23	22	true	positive	Acceleration of ventricular rate and/or ventricular fibrillation has been reported in patients with atrial flutter or atrial fibrillation and a coexisting accessory AV pathway following administration of verapamil [see Warnings and Precautions (5.4)].  Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  		0	11170	1046801	11170
basis	Verapamil	23	25	true	positive	Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  It is not known whether this action is important at the doses used in man.  Hemodynamics    Verapamil reduces afterload and myocardial contractility.  		0	11170	1046801	11170
basis	Verapamil	23	25	true	positive	Verapamil has a local anesthetic action that is 1.6 times that of procaine on an equimolar basis.  It is not known whether this action is important at the doses used in man.  Hemodynamics    Verapamil reduces afterload and myocardial contractility.  		0	11170	1046801	11170
verapamil	Norverapamil	42	44	false	none	Consumption of a high fat meal just prior to dosing in the morning had no effect on the extent of absorption and a modest effect on the rate of absorption from verapamil hydrochloride extended-release capsules (PM).  The rate of absorption was not affected by whether the volunteers were supine 2 hours after night-time dosing or nonsupine for 4 hours following morning dosing.  Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		11170	none	11170	none
verapamil	Norverapamil	42	44	false	none	Consumption of a high fat meal just prior to dosing in the morning had no effect on the extent of absorption and a modest effect on the rate of absorption from verapamil hydrochloride extended-release capsules (PM).  The rate of absorption was not affected by whether the volunteers were supine 2 hours after night-time dosing or nonsupine for 4 hours following morning dosing.  Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		11170	none	11170	none
verapamil	Norverapamil	46	46	false	none	Similar results were observed with norverapamil.  		11170	none	11170	none
verapamil	Norverapamil	46	46	false	none	Similar results were observed with norverapamil.  		11170	none	11170	none
verapamil	Norverapamil	46	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		11170	none	11170	none
verapamil	Norverapamil	46	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		11170	none	11170	none
verapamil	Norverapamil	47	46	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  		11170	none	11170	none
verapamil	Norverapamil	47	46	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  		11170	none	11170	none
verapamil	Norverapamil	44	46	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		11170	none	11170	none
verapamil	Norverapamil	44	46	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		11170	none	11170	none
verapamil	Norverapamil	44	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		11170	none	11170	none
verapamil	Norverapamil	44	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		11170	none	11170	none
verapamil	Norverapamil	45	46	false	none	When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		11170	none	11170	none
verapamil	Norverapamil	45	46	false	none	When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		11170	none	11170	none
verapamil	Norverapamil	45	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  		11170	none	11170	none
verapamil	Norverapamil	45	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  		11170	none	11170	none
verapamil	Norverapamil	48	46	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  Racemic verapamil is released from verapamil hydrochloride extended-release capsules (PM) by diffusion following the gradual solubilization of the water soluble polymer.  		11170	none	11170	none
verapamil	Norverapamil	48	46	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  Racemic verapamil is released from verapamil hydrochloride extended-release capsules (PM) by diffusion following the gradual solubilization of the water soluble polymer.  		11170	none	11170	none
verapamil	Norverapamil	63	64	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		11170	none	11170	none
verapamil	Norverapamil	63	64	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		11170	none	11170	none
verapamil	Norverapamil	63	65	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	none	11170	none
verapamil	Norverapamil	63	65	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	none	11170	none
verapamil	Norverapamil	63	63	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  		11170	none	11170	none
verapamil	Norverapamil	63	63	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  		11170	none	11170	none
verapamil	Norverapamil	71	73	false	none	In addition, in these patients there is a reduced first pass effect, and verapamil is more bioavailable.  Verapamil clearance values suggest that patients with liver dysfunction may attain therapeutic verapamil plasma concentrations with one third of the oral daily dose required for patients with normal liver function.  After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  		11170	none	11170	none
verapamil	Norverapamil	71	73	false	none	In addition, in these patients there is a reduced first pass effect, and verapamil is more bioavailable.  Verapamil clearance values suggest that patients with liver dysfunction may attain therapeutic verapamil plasma concentrations with one third of the oral daily dose required for patients with normal liver function.  After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  		11170	none	11170	none
verapamil	Norverapamil	64	64	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		11170	none	11170	none
verapamil	Norverapamil	64	64	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		11170	none	11170	none
verapamil	Norverapamil	64	65	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	none	11170	none
verapamil	Norverapamil	64	65	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	none	11170	none
verapamil	Norverapamil	64	63	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		11170	none	11170	none
verapamil	Norverapamil	64	63	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		11170	none	11170	none
verapamil	Norverapamil	65	64	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	none	11170	none
verapamil	Norverapamil	65	64	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	none	11170	none
verapamil	Norverapamil	65	65	false	none	The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	none	11170	none
verapamil	Norverapamil	65	65	false	none	The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	none	11170	none
verapamil	Norverapamil	65	63	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	none	11170	none
verapamil	Norverapamil	65	63	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	none	11170	none
verapamil	Norverapamil	72	73	false	none	Verapamil clearance values suggest that patients with liver dysfunction may attain therapeutic verapamil plasma concentrations with one third of the oral daily dose required for patients with normal liver function.  After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  		11170	none	11170	none
verapamil	Norverapamil	72	73	false	none	Verapamil clearance values suggest that patients with liver dysfunction may attain therapeutic verapamil plasma concentrations with one third of the oral daily dose required for patients with normal liver function.  After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  		11170	none	11170	none
verapamil	Norverapamil	73	73	false	none	After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  		11170	none	11170	none
verapamil	Norverapamil	73	73	false	none	After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  		11170	none	11170	none
verapamil	Norverapamil	74	73	false	none	After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  Geriatric Use    The pharmacokinetics of verapamil GITS were studied after 5 consecutive nights of dosing 180 mg in 30 healthy young (19 to 43 years) vs. 30 healthy elderly (65 to 80 years) male and female subjects.  		11170	none	11170	none
verapamil	Norverapamil	74	73	false	none	After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  Geriatric Use    The pharmacokinetics of verapamil GITS were studied after 5 consecutive nights of dosing 180 mg in 30 healthy young (19 to 43 years) vs. 30 healthy elderly (65 to 80 years) male and female subjects.  		11170	none	11170	none
verapamil	Norverapamil	75	73	false	none	After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  Geriatric Use    The pharmacokinetics of verapamil GITS were studied after 5 consecutive nights of dosing 180 mg in 30 healthy young (19 to 43 years) vs. 30 healthy elderly (65 to 80 years) male and female subjects.  Older subjects had significantly higher mean verapamil Cmax, Cmin and AUC(0-24h) compared to younger subjects.  		11170	none	11170	none
verapamil	Norverapamil	75	73	false	none	After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  Geriatric Use    The pharmacokinetics of verapamil GITS were studied after 5 consecutive nights of dosing 180 mg in 30 healthy young (19 to 43 years) vs. 30 healthy elderly (65 to 80 years) male and female subjects.  Older subjects had significantly higher mean verapamil Cmax, Cmin and AUC(0-24h) compared to younger subjects.  		11170	none	11170	none
verapamil	relaxant	29	30	false	none	Pulmonary Function    Verapamil does not induce bronchoconstriction and, hence, does not impair ventilatory function.  Verapamil has been shown to have either a neutral or relaxant effect on bronchial smooth muscle.  		11170	none	11170	none
verapamil	relaxant	29	30	false	none	Pulmonary Function    Verapamil does not induce bronchoconstriction and, hence, does not impair ventilatory function.  Verapamil has been shown to have either a neutral or relaxant effect on bronchial smooth muscle.  		11170	none	11170	none
verapamil	relaxant	31	30	false	none	Verapamil has been shown to have either a neutral or relaxant effect on bronchial smooth muscle.  12.3 Pharmacokinetics    Verapamil is administered as a racemic mixture of the R and S enantiomers.  		11170	none	11170	none
verapamil	relaxant	31	30	false	none	Verapamil has been shown to have either a neutral or relaxant effect on bronchial smooth muscle.  12.3 Pharmacokinetics    Verapamil is administered as a racemic mixture of the R and S enantiomers.  		11170	none	11170	none
verapamil	relaxant	30	30	true	negative	Verapamil has been shown to have either a neutral or relaxant effect on bronchial smooth muscle.  		11170	none	11170	none
verapamil	relaxant	30	30	true	negative	Verapamil has been shown to have either a neutral or relaxant effect on bronchial smooth muscle.  		11170	none	11170	none
verapamil	norverapamil	42	44	false	none	Consumption of a high fat meal just prior to dosing in the morning had no effect on the extent of absorption and a modest effect on the rate of absorption from verapamil hydrochloride extended-release capsules (PM).  The rate of absorption was not affected by whether the volunteers were supine 2 hours after night-time dosing or nonsupine for 4 hours following morning dosing.  Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		11170	none	11170	C016904
verapamil	norverapamil	42	44	false	none	Consumption of a high fat meal just prior to dosing in the morning had no effect on the extent of absorption and a modest effect on the rate of absorption from verapamil hydrochloride extended-release capsules (PM).  The rate of absorption was not affected by whether the volunteers were supine 2 hours after night-time dosing or nonsupine for 4 hours following morning dosing.  Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		11170	none	11170	C016904
verapamil	norverapamil	46	46	false	none	Similar results were observed with norverapamil.  		11170	none	11170	C016904
verapamil	norverapamil	46	46	false	none	Similar results were observed with norverapamil.  		11170	none	11170	C016904
verapamil	norverapamil	46	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		11170	none	11170	C016904
verapamil	norverapamil	46	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		11170	none	11170	C016904
verapamil	norverapamil	47	46	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  		11170	none	11170	C016904
verapamil	norverapamil	47	46	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  		11170	none	11170	C016904
verapamil	norverapamil	44	46	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		11170	none	11170	C016904
verapamil	norverapamil	44	46	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		11170	none	11170	C016904
verapamil	norverapamil	44	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		11170	none	11170	C016904
verapamil	norverapamil	44	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		11170	none	11170	C016904
verapamil	norverapamil	45	46	false	none	When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		11170	none	11170	C016904
verapamil	norverapamil	45	46	false	none	When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		11170	none	11170	C016904
verapamil	norverapamil	45	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  		11170	none	11170	C016904
verapamil	norverapamil	45	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  		11170	none	11170	C016904
verapamil	norverapamil	48	46	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  Racemic verapamil is released from verapamil hydrochloride extended-release capsules (PM) by diffusion following the gradual solubilization of the water soluble polymer.  		11170	none	11170	C016904
verapamil	norverapamil	48	46	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  Racemic verapamil is released from verapamil hydrochloride extended-release capsules (PM) by diffusion following the gradual solubilization of the water soluble polymer.  		11170	none	11170	C016904
verapamil	norverapamil	63	64	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		11170	none	11170	C016904
verapamil	norverapamil	63	64	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		11170	none	11170	C016904
verapamil	norverapamil	63	65	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	none	11170	C016904
verapamil	norverapamil	63	65	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	none	11170	C016904
verapamil	norverapamil	63	63	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  		11170	none	11170	C016904
verapamil	norverapamil	63	63	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  		11170	none	11170	C016904
verapamil	norverapamil	71	73	false	none	In addition, in these patients there is a reduced first pass effect, and verapamil is more bioavailable.  Verapamil clearance values suggest that patients with liver dysfunction may attain therapeutic verapamil plasma concentrations with one third of the oral daily dose required for patients with normal liver function.  After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  		11170	none	11170	C016904
verapamil	norverapamil	71	73	false	none	In addition, in these patients there is a reduced first pass effect, and verapamil is more bioavailable.  Verapamil clearance values suggest that patients with liver dysfunction may attain therapeutic verapamil plasma concentrations with one third of the oral daily dose required for patients with normal liver function.  After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  		11170	none	11170	C016904
verapamil	norverapamil	64	64	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		11170	none	11170	C016904
verapamil	norverapamil	64	64	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		11170	none	11170	C016904
verapamil	norverapamil	64	65	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	none	11170	C016904
verapamil	norverapamil	64	65	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	none	11170	C016904
verapamil	norverapamil	64	63	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		11170	none	11170	C016904
verapamil	norverapamil	64	63	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		11170	none	11170	C016904
verapamil	norverapamil	65	64	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	none	11170	C016904
verapamil	norverapamil	65	64	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	none	11170	C016904
verapamil	norverapamil	65	65	false	none	The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	none	11170	C016904
verapamil	norverapamil	65	65	false	none	The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	none	11170	C016904
verapamil	norverapamil	65	63	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	none	11170	C016904
verapamil	norverapamil	65	63	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	none	11170	C016904
verapamil	norverapamil	72	73	false	none	Verapamil clearance values suggest that patients with liver dysfunction may attain therapeutic verapamil plasma concentrations with one third of the oral daily dose required for patients with normal liver function.  After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  		11170	none	11170	C016904
verapamil	norverapamil	72	73	false	none	Verapamil clearance values suggest that patients with liver dysfunction may attain therapeutic verapamil plasma concentrations with one third of the oral daily dose required for patients with normal liver function.  After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  		11170	none	11170	C016904
verapamil	norverapamil	73	73	false	none	After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  		11170	none	11170	C016904
verapamil	norverapamil	73	73	false	none	After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  		11170	none	11170	C016904
verapamil	norverapamil	74	73	false	none	After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  Geriatric Use    The pharmacokinetics of verapamil GITS were studied after 5 consecutive nights of dosing 180 mg in 30 healthy young (19 to 43 years) vs. 30 healthy elderly (65 to 80 years) male and female subjects.  		11170	none	11170	C016904
verapamil	norverapamil	74	73	false	none	After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  Geriatric Use    The pharmacokinetics of verapamil GITS were studied after 5 consecutive nights of dosing 180 mg in 30 healthy young (19 to 43 years) vs. 30 healthy elderly (65 to 80 years) male and female subjects.  		11170	none	11170	C016904
verapamil	norverapamil	75	73	false	none	After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  Geriatric Use    The pharmacokinetics of verapamil GITS were studied after 5 consecutive nights of dosing 180 mg in 30 healthy young (19 to 43 years) vs. 30 healthy elderly (65 to 80 years) male and female subjects.  Older subjects had significantly higher mean verapamil Cmax, Cmin and AUC(0-24h) compared to younger subjects.  		11170	none	11170	C016904
verapamil	norverapamil	75	73	false	none	After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  Geriatric Use    The pharmacokinetics of verapamil GITS were studied after 5 consecutive nights of dosing 180 mg in 30 healthy young (19 to 43 years) vs. 30 healthy elderly (65 to 80 years) male and female subjects.  Older subjects had significantly higher mean verapamil Cmax, Cmin and AUC(0-24h) compared to younger subjects.  		11170	none	11170	C016904
verapamil	p450	59	61	false	none	Metabolism and Excretion    Orally administered verapamil undergoes extensive metabolism in the liver.  Verapamil is metabolized by O-demethylation (25%) and N-dealkylation (40%), and is subject to pre-systemic hepatic metabolism with elimination of up to 80% of the dose.  The metabolism is mediated by hepatic cytochrome P450, and animal studies have implied that the mono-oxygenase is the specific isoenzyme of the P450 family.  		11170	none	11170	none
verapamil	p450	59	61	false	none	Metabolism and Excretion    Orally administered verapamil undergoes extensive metabolism in the liver.  Verapamil is metabolized by O-demethylation (25%) and N-dealkylation (40%), and is subject to pre-systemic hepatic metabolism with elimination of up to 80% of the dose.  The metabolism is mediated by hepatic cytochrome P450, and animal studies have implied that the mono-oxygenase is the specific isoenzyme of the P450 family.  		11170	none	11170	none
verapamil	p450	63	61	false	none	The metabolism is mediated by hepatic cytochrome P450, and animal studies have implied that the mono-oxygenase is the specific isoenzyme of the P450 family.  Thirteen metabolites have been identified in urine.  Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  		11170	none	11170	none
verapamil	p450	63	61	false	none	The metabolism is mediated by hepatic cytochrome P450, and animal studies have implied that the mono-oxygenase is the specific isoenzyme of the P450 family.  Thirteen metabolites have been identified in urine.  Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  		11170	none	11170	none
verapamil	p450	60	61	false	none	Verapamil is metabolized by O-demethylation (25%) and N-dealkylation (40%), and is subject to pre-systemic hepatic metabolism with elimination of up to 80% of the dose.  The metabolism is mediated by hepatic cytochrome P450, and animal studies have implied that the mono-oxygenase is the specific isoenzyme of the P450 family.  		11170	none	11170	none
verapamil	p450	60	61	false	none	Verapamil is metabolized by O-demethylation (25%) and N-dealkylation (40%), and is subject to pre-systemic hepatic metabolism with elimination of up to 80% of the dose.  The metabolism is mediated by hepatic cytochrome P450, and animal studies have implied that the mono-oxygenase is the specific isoenzyme of the P450 family.  		11170	none	11170	none
Norverapamil	verapamil hydrochloride	64	64	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		none	0	none	D014700
Norverapamil	verapamil hydrochloride	64	64	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		none	0	none	D014700
Norverapamil	verapamil hydrochloride	65	64	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		none	0	none	D014700
Norverapamil	verapamil hydrochloride	65	64	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		none	0	none	D014700
Norverapamil	verapamil hydrochloride	63	64	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		none	0	none	D014700
Norverapamil	verapamil hydrochloride	63	64	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		none	0	none	D014700
Norverapamil	verapamil hydrochloride	46	48	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  Racemic verapamil is released from verapamil hydrochloride extended-release capsules (PM) by diffusion following the gradual solubilization of the water soluble polymer.  		none	0	none	D014700
Norverapamil	verapamil hydrochloride	46	48	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  Racemic verapamil is released from verapamil hydrochloride extended-release capsules (PM) by diffusion following the gradual solubilization of the water soluble polymer.  		none	0	none	D014700
Norverapamil	verapamil hydrochloride	46	47	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  		none	0	none	D014700
Norverapamil	verapamil hydrochloride	46	47	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  		none	0	none	D014700
Norverapamil	verapamil hydrochloride	46	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		none	0	none	D014700
Norverapamil	verapamil hydrochloride	46	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		none	0	none	D014700
Norverapamil	verapamil hydrochloride	46	45	false	none	When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		none	0	none	D014700
Norverapamil	verapamil hydrochloride	46	45	false	none	When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		none	0	none	D014700
Norverapamil	verapamil hydrochloride	44	42	false	none	Consumption of a high fat meal just prior to dosing in the morning had no effect on the extent of absorption and a modest effect on the rate of absorption from verapamil hydrochloride extended-release capsules (PM).  The rate of absorption was not affected by whether the volunteers were supine 2 hours after night-time dosing or nonsupine for 4 hours following morning dosing.  Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		none	0	none	D014700
Norverapamil	verapamil hydrochloride	44	42	false	none	Consumption of a high fat meal just prior to dosing in the morning had no effect on the extent of absorption and a modest effect on the rate of absorption from verapamil hydrochloride extended-release capsules (PM).  The rate of absorption was not affected by whether the volunteers were supine 2 hours after night-time dosing or nonsupine for 4 hours following morning dosing.  Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		none	0	none	D014700
Norverapamil	verapamil hydrochloride	44	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		none	0	none	D014700
Norverapamil	verapamil hydrochloride	44	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		none	0	none	D014700
Norverapamil	verapamil hydrochloride	44	45	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  		none	0	none	D014700
Norverapamil	verapamil hydrochloride	44	45	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  		none	0	none	D014700
Norverapamil	Verapamil	64	63	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		none	11170	none	11170
Norverapamil	Verapamil	64	63	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		none	11170	none	11170
Norverapamil	Verapamil	64	64	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		none	11170	none	11170
Norverapamil	Verapamil	64	64	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		none	11170	none	11170
Norverapamil	Verapamil	64	65	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		none	11170	none	11170
Norverapamil	Verapamil	64	65	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		none	11170	none	11170
Norverapamil	Verapamil	65	63	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		none	11170	none	11170
Norverapamil	Verapamil	65	63	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		none	11170	none	11170
Norverapamil	Verapamil	65	64	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		none	11170	none	11170
Norverapamil	Verapamil	65	64	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		none	11170	none	11170
Norverapamil	Verapamil	65	65	false	none	The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		none	11170	none	11170
Norverapamil	Verapamil	65	65	false	none	The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		none	11170	none	11170
Norverapamil	Verapamil	63	63	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  		none	11170	none	11170
Norverapamil	Verapamil	63	63	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  		none	11170	none	11170
Norverapamil	Verapamil	63	64	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		none	11170	none	11170
Norverapamil	Verapamil	63	64	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		none	11170	none	11170
Norverapamil	Verapamil	63	65	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		none	11170	none	11170
Norverapamil	Verapamil	63	65	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		none	11170	none	11170
Norverapamil	Verapamil	46	46	false	none	Similar results were observed with norverapamil.  		none	11170	none	11170
Norverapamil	Verapamil	46	46	false	none	Similar results were observed with norverapamil.  		none	11170	none	11170
Norverapamil	Verapamil	46	47	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  		none	11170	none	11170
Norverapamil	Verapamil	46	47	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  		none	11170	none	11170
Norverapamil	Verapamil	46	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		none	11170	none	11170
Norverapamil	Verapamil	46	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		none	11170	none	11170
Norverapamil	Verapamil	46	45	false	none	When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		none	11170	none	11170
Norverapamil	Verapamil	46	45	false	none	When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		none	11170	none	11170
Norverapamil	Verapamil	46	48	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  Racemic verapamil is released from verapamil hydrochloride extended-release capsules (PM) by diffusion following the gradual solubilization of the water soluble polymer.  		none	11170	none	11170
Norverapamil	Verapamil	46	48	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  Racemic verapamil is released from verapamil hydrochloride extended-release capsules (PM) by diffusion following the gradual solubilization of the water soluble polymer.  		none	11170	none	11170
Norverapamil	Verapamil	73	71	false	none	In addition, in these patients there is a reduced first pass effect, and verapamil is more bioavailable.  Verapamil clearance values suggest that patients with liver dysfunction may attain therapeutic verapamil plasma concentrations with one third of the oral daily dose required for patients with normal liver function.  After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  		none	11170	none	11170
Norverapamil	Verapamil	73	71	false	none	In addition, in these patients there is a reduced first pass effect, and verapamil is more bioavailable.  Verapamil clearance values suggest that patients with liver dysfunction may attain therapeutic verapamil plasma concentrations with one third of the oral daily dose required for patients with normal liver function.  After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  		none	11170	none	11170
Norverapamil	Verapamil	73	72	false	none	Verapamil clearance values suggest that patients with liver dysfunction may attain therapeutic verapamil plasma concentrations with one third of the oral daily dose required for patients with normal liver function.  After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  		none	11170	none	11170
Norverapamil	Verapamil	73	72	false	none	Verapamil clearance values suggest that patients with liver dysfunction may attain therapeutic verapamil plasma concentrations with one third of the oral daily dose required for patients with normal liver function.  After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  		none	11170	none	11170
Norverapamil	Verapamil	73	73	false	none	After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  		none	11170	none	11170
Norverapamil	Verapamil	73	73	false	none	After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  		none	11170	none	11170
Norverapamil	Verapamil	73	74	false	none	After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  Geriatric Use    The pharmacokinetics of verapamil GITS were studied after 5 consecutive nights of dosing 180 mg in 30 healthy young (19 to 43 years) vs. 30 healthy elderly (65 to 80 years) male and female subjects.  		none	11170	none	11170
Norverapamil	Verapamil	73	74	false	none	After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  Geriatric Use    The pharmacokinetics of verapamil GITS were studied after 5 consecutive nights of dosing 180 mg in 30 healthy young (19 to 43 years) vs. 30 healthy elderly (65 to 80 years) male and female subjects.  		none	11170	none	11170
Norverapamil	Verapamil	73	75	false	none	After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  Geriatric Use    The pharmacokinetics of verapamil GITS were studied after 5 consecutive nights of dosing 180 mg in 30 healthy young (19 to 43 years) vs. 30 healthy elderly (65 to 80 years) male and female subjects.  Older subjects had significantly higher mean verapamil Cmax, Cmin and AUC(0-24h) compared to younger subjects.  		none	11170	none	11170
Norverapamil	Verapamil	73	75	false	none	After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  Geriatric Use    The pharmacokinetics of verapamil GITS were studied after 5 consecutive nights of dosing 180 mg in 30 healthy young (19 to 43 years) vs. 30 healthy elderly (65 to 80 years) male and female subjects.  Older subjects had significantly higher mean verapamil Cmax, Cmin and AUC(0-24h) compared to younger subjects.  		none	11170	none	11170
Norverapamil	Verapamil	44	42	false	none	Consumption of a high fat meal just prior to dosing in the morning had no effect on the extent of absorption and a modest effect on the rate of absorption from verapamil hydrochloride extended-release capsules (PM).  The rate of absorption was not affected by whether the volunteers were supine 2 hours after night-time dosing or nonsupine for 4 hours following morning dosing.  Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		none	11170	none	11170
Norverapamil	Verapamil	44	42	false	none	Consumption of a high fat meal just prior to dosing in the morning had no effect on the extent of absorption and a modest effect on the rate of absorption from verapamil hydrochloride extended-release capsules (PM).  The rate of absorption was not affected by whether the volunteers were supine 2 hours after night-time dosing or nonsupine for 4 hours following morning dosing.  Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		none	11170	none	11170
Norverapamil	Verapamil	44	46	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		none	11170	none	11170
Norverapamil	Verapamil	44	46	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		none	11170	none	11170
Norverapamil	Verapamil	44	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		none	11170	none	11170
Norverapamil	Verapamil	44	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		none	11170	none	11170
Norverapamil	Verapamil	44	45	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  		none	11170	none	11170
Norverapamil	Verapamil	44	45	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  		none	11170	none	11170
Norverapamil	p450	63	61	false	none	The metabolism is mediated by hepatic cytochrome P450, and animal studies have implied that the mono-oxygenase is the specific isoenzyme of the P450 family.  Thirteen metabolites have been identified in urine.  Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  		none	none	none	none
relaxant	Verapamil	30	29	false	none	Pulmonary Function    Verapamil does not induce bronchoconstriction and, hence, does not impair ventilatory function.  Verapamil has been shown to have either a neutral or relaxant effect on bronchial smooth muscle.  		none	11170	none	11170
relaxant	Verapamil	30	29	false	none	Pulmonary Function    Verapamil does not induce bronchoconstriction and, hence, does not impair ventilatory function.  Verapamil has been shown to have either a neutral or relaxant effect on bronchial smooth muscle.  		none	11170	none	11170
relaxant	Verapamil	30	31	false	none	Verapamil has been shown to have either a neutral or relaxant effect on bronchial smooth muscle.  12.3 Pharmacokinetics    Verapamil is administered as a racemic mixture of the R and S enantiomers.  		none	11170	none	11170
relaxant	Verapamil	30	31	false	none	Verapamil has been shown to have either a neutral or relaxant effect on bronchial smooth muscle.  12.3 Pharmacokinetics    Verapamil is administered as a racemic mixture of the R and S enantiomers.  		none	11170	none	11170
relaxant	Verapamil	30	30	true	negative	Verapamil has been shown to have either a neutral or relaxant effect on bronchial smooth muscle.  		none	11170	none	11170
relaxant	Verapamil	30	30	true	negative	Verapamil has been shown to have either a neutral or relaxant effect on bronchial smooth muscle.  		none	11170	none	11170
verapamil hydrochloride	Verapamil	48	46	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  Racemic verapamil is released from verapamil hydrochloride extended-release capsules (PM) by diffusion following the gradual solubilization of the water soluble polymer.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	48	46	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  Racemic verapamil is released from verapamil hydrochloride extended-release capsules (PM) by diffusion following the gradual solubilization of the water soluble polymer.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	48	47	true	positive	Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  Racemic verapamil is released from verapamil hydrochloride extended-release capsules (PM) by diffusion following the gradual solubilization of the water soluble polymer.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	48	47	true	positive	Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  Racemic verapamil is released from verapamil hydrochloride extended-release capsules (PM) by diffusion following the gradual solubilization of the water soluble polymer.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	48	48	false	none	Racemic verapamil is released from verapamil hydrochloride extended-release capsules (PM) by diffusion following the gradual solubilization of the water soluble polymer.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	48	48	false	none	Racemic verapamil is released from verapamil hydrochloride extended-release capsules (PM) by diffusion following the gradual solubilization of the water soluble polymer.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	64	63	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	64	63	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	64	64	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	64	64	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	64	65	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	64	65	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	54	55	true	positive	In healthy volunteers, following administration of verapamil hydrochloride extended-release capsules (PM) (200 mg per day), steady-state pharmacokinetics of the R and S enantiomers of verapamil is as follows: Mean Cmax of the R isomer was 77.8 ng/ml and 16.8 ng/ml for the S isomer; AUC(0-24h) of the R isomer was 1037 ng•h/ml and 195 ng•h/ml for the S isomer.  In general, bioavailability of verapamil is higher and half-life longer in older (> 65 yrs) subjects.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	54	55	true	positive	In healthy volunteers, following administration of verapamil hydrochloride extended-release capsules (PM) (200 mg per day), steady-state pharmacokinetics of the R and S enantiomers of verapamil is as follows: Mean Cmax of the R isomer was 77.8 ng/ml and 16.8 ng/ml for the S isomer; AUC(0-24h) of the R isomer was 1037 ng•h/ml and 195 ng•h/ml for the S isomer.  In general, bioavailability of verapamil is higher and half-life longer in older (> 65 yrs) subjects.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	54	54	true	positive	In healthy volunteers, following administration of verapamil hydrochloride extended-release capsules (PM) (200 mg per day), steady-state pharmacokinetics of the R and S enantiomers of verapamil is as follows: Mean Cmax of the R isomer was 77.8 ng/ml and 16.8 ng/ml for the S isomer; AUC(0-24h) of the R isomer was 1037 ng•h/ml and 195 ng•h/ml for the S isomer.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	54	54	true	positive	In healthy volunteers, following administration of verapamil hydrochloride extended-release capsules (PM) (200 mg per day), steady-state pharmacokinetics of the R and S enantiomers of verapamil is as follows: Mean Cmax of the R isomer was 77.8 ng/ml and 16.8 ng/ml for the S isomer; AUC(0-24h) of the R isomer was 1037 ng•h/ml and 195 ng•h/ml for the S isomer.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	36	34	true	positive	Absorption    In a study in five subjects with oral immediate-release verapamil, the systemic bioavailability was from 33% to 65% for the R enantiomer and from 13% to 34% for the S enantiomer.  Following oral administration of an immediately releasing formulation every 8 hours in 24 subjects, the relative systemic availability of the S enantiomer compared to the R enantiomer was approximately 13% following a single day's administration and approximately 18% following administration to steady-state.  The degree of stereoselectivity of metabolism for verapamil hydrochloride extended-release capsules (PM) was similar to that for the immediate-release formulation.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	36	34	true	positive	Absorption    In a study in five subjects with oral immediate-release verapamil, the systemic bioavailability was from 33% to 65% for the R enantiomer and from 13% to 34% for the S enantiomer.  Following oral administration of an immediately releasing formulation every 8 hours in 24 subjects, the relative systemic availability of the S enantiomer compared to the R enantiomer was approximately 13% following a single day's administration and approximately 18% following administration to steady-state.  The degree of stereoselectivity of metabolism for verapamil hydrochloride extended-release capsules (PM) was similar to that for the immediate-release formulation.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	36	36	false	none	The degree of stereoselectivity of metabolism for verapamil hydrochloride extended-release capsules (PM) was similar to that for the immediate-release formulation.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	36	36	false	none	The degree of stereoselectivity of metabolism for verapamil hydrochloride extended-release capsules (PM) was similar to that for the immediate-release formulation.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	42	42	false	none	Consumption of a high fat meal just prior to dosing in the morning had no effect on the extent of absorption and a modest effect on the rate of absorption from verapamil hydrochloride extended-release capsules (PM).  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	42	42	false	none	Consumption of a high fat meal just prior to dosing in the morning had no effect on the extent of absorption and a modest effect on the rate of absorption from verapamil hydrochloride extended-release capsules (PM).  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	42	41	false	none	Dose escalation study data indicate that verapamil concentrations increase disproportionally to dose as measured by relative peak plasma concentrations (Cmax) or areas under the plasma concentration vs. time curves (AUC).  Consumption of a high fat meal just prior to dosing in the morning had no effect on the extent of absorption and a modest effect on the rate of absorption from verapamil hydrochloride extended-release capsules (PM).  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	42	41	false	none	Dose escalation study data indicate that verapamil concentrations increase disproportionally to dose as measured by relative peak plasma concentrations (Cmax) or areas under the plasma concentration vs. time curves (AUC).  Consumption of a high fat meal just prior to dosing in the morning had no effect on the extent of absorption and a modest effect on the rate of absorption from verapamil hydrochloride extended-release capsules (PM).  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	42	44	false	none	Consumption of a high fat meal just prior to dosing in the morning had no effect on the extent of absorption and a modest effect on the rate of absorption from verapamil hydrochloride extended-release capsules (PM).  The rate of absorption was not affected by whether the volunteers were supine 2 hours after night-time dosing or nonsupine for 4 hours following morning dosing.  Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	42	44	false	none	Consumption of a high fat meal just prior to dosing in the morning had no effect on the extent of absorption and a modest effect on the rate of absorption from verapamil hydrochloride extended-release capsules (PM).  The rate of absorption was not affected by whether the volunteers were supine 2 hours after night-time dosing or nonsupine for 4 hours following morning dosing.  Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	57	55	false	none	In general, bioavailability of verapamil is higher and half-life longer in older (> 65 yrs) subjects.  Lean body weight also affects its pharmacokinetics inversely.  It was not possible to observe a gender difference in the clinical trials of verapamil hydrochloride extended-release capsules (PM) due to the small sample size.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	57	55	false	none	In general, bioavailability of verapamil is higher and half-life longer in older (> 65 yrs) subjects.  Lean body weight also affects its pharmacokinetics inversely.  It was not possible to observe a gender difference in the clinical trials of verapamil hydrochloride extended-release capsules (PM) due to the small sample size.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	57	59	false	none	It was not possible to observe a gender difference in the clinical trials of verapamil hydrochloride extended-release capsules (PM) due to the small sample size.  However, there are conflicting data in the literature suggesting that verapamil clearance decreased with age in women to a greater degree than in men.  Metabolism and Excretion    Orally administered verapamil undergoes extensive metabolism in the liver.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	57	59	false	none	It was not possible to observe a gender difference in the clinical trials of verapamil hydrochloride extended-release capsules (PM) due to the small sample size.  However, there are conflicting data in the literature suggesting that verapamil clearance decreased with age in women to a greater degree than in men.  Metabolism and Excretion    Orally administered verapamil undergoes extensive metabolism in the liver.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	57	58	false	none	It was not possible to observe a gender difference in the clinical trials of verapamil hydrochloride extended-release capsules (PM) due to the small sample size.  However, there are conflicting data in the literature suggesting that verapamil clearance decreased with age in women to a greater degree than in men.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	57	58	false	none	It was not possible to observe a gender difference in the clinical trials of verapamil hydrochloride extended-release capsules (PM) due to the small sample size.  However, there are conflicting data in the literature suggesting that verapamil clearance decreased with age in women to a greater degree than in men.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	57	57	false	none	It was not possible to observe a gender difference in the clinical trials of verapamil hydrochloride extended-release capsules (PM) due to the small sample size.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	57	57	false	none	It was not possible to observe a gender difference in the clinical trials of verapamil hydrochloride extended-release capsules (PM) due to the small sample size.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	47	46	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	47	46	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	47	47	true	positive	Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	47	47	true	positive	Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	47	45	true	positive	When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	47	45	true	positive	When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	47	48	true	positive	Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  Racemic verapamil is released from verapamil hydrochloride extended-release capsules (PM) by diffusion following the gradual solubilization of the water soluble polymer.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	47	48	true	positive	Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  Racemic verapamil is released from verapamil hydrochloride extended-release capsules (PM) by diffusion following the gradual solubilization of the water soluble polymer.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	44	42	false	none	Consumption of a high fat meal just prior to dosing in the morning had no effect on the extent of absorption and a modest effect on the rate of absorption from verapamil hydrochloride extended-release capsules (PM).  The rate of absorption was not affected by whether the volunteers were supine 2 hours after night-time dosing or nonsupine for 4 hours following morning dosing.  Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	44	42	false	none	Consumption of a high fat meal just prior to dosing in the morning had no effect on the extent of absorption and a modest effect on the rate of absorption from verapamil hydrochloride extended-release capsules (PM).  The rate of absorption was not affected by whether the volunteers were supine 2 hours after night-time dosing or nonsupine for 4 hours following morning dosing.  Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	44	46	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	44	46	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	44	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	44	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	44	45	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	44	45	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	45	46	false	none	When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	45	46	false	none	When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	45	47	true	positive	When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	45	47	true	positive	When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	45	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	45	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	45	45	false	none	When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  		0	11170	D014700	11170
verapamil hydrochloride	Verapamil	45	45	false	none	When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  		0	11170	D014700	11170
verapamil hydrochloride	norverapamil	48	46	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  Racemic verapamil is released from verapamil hydrochloride extended-release capsules (PM) by diffusion following the gradual solubilization of the water soluble polymer.  		0	none	D014700	C016904
verapamil hydrochloride	norverapamil	48	46	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  Racemic verapamil is released from verapamil hydrochloride extended-release capsules (PM) by diffusion following the gradual solubilization of the water soluble polymer.  		0	none	D014700	C016904
verapamil hydrochloride	norverapamil	64	64	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		0	none	D014700	C016904
verapamil hydrochloride	norverapamil	64	64	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		0	none	D014700	C016904
verapamil hydrochloride	norverapamil	64	65	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		0	none	D014700	C016904
verapamil hydrochloride	norverapamil	64	65	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		0	none	D014700	C016904
verapamil hydrochloride	norverapamil	64	63	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		0	none	D014700	C016904
verapamil hydrochloride	norverapamil	64	63	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		0	none	D014700	C016904
verapamil hydrochloride	norverapamil	42	44	false	none	Consumption of a high fat meal just prior to dosing in the morning had no effect on the extent of absorption and a modest effect on the rate of absorption from verapamil hydrochloride extended-release capsules (PM).  The rate of absorption was not affected by whether the volunteers were supine 2 hours after night-time dosing or nonsupine for 4 hours following morning dosing.  Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		0	none	D014700	C016904
verapamil hydrochloride	norverapamil	42	44	false	none	Consumption of a high fat meal just prior to dosing in the morning had no effect on the extent of absorption and a modest effect on the rate of absorption from verapamil hydrochloride extended-release capsules (PM).  The rate of absorption was not affected by whether the volunteers were supine 2 hours after night-time dosing or nonsupine for 4 hours following morning dosing.  Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		0	none	D014700	C016904
verapamil hydrochloride	norverapamil	47	46	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  		0	none	D014700	C016904
verapamil hydrochloride	norverapamil	47	46	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  		0	none	D014700	C016904
verapamil hydrochloride	norverapamil	44	46	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		0	none	D014700	C016904
verapamil hydrochloride	norverapamil	44	46	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		0	none	D014700	C016904
verapamil hydrochloride	norverapamil	44	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		0	none	D014700	C016904
verapamil hydrochloride	norverapamil	44	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		0	none	D014700	C016904
verapamil hydrochloride	norverapamil	45	46	false	none	When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		0	none	D014700	C016904
verapamil hydrochloride	norverapamil	45	46	false	none	When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		0	none	D014700	C016904
verapamil hydrochloride	norverapamil	45	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  		0	none	D014700	C016904
verapamil hydrochloride	norverapamil	45	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  		0	none	D014700	C016904
Verapamil	norverapamil	42	44	false	none	Consumption of a high fat meal just prior to dosing in the morning had no effect on the extent of absorption and a modest effect on the rate of absorption from verapamil hydrochloride extended-release capsules (PM).  The rate of absorption was not affected by whether the volunteers were supine 2 hours after night-time dosing or nonsupine for 4 hours following morning dosing.  Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		11170	none	11170	C016904
Verapamil	norverapamil	42	44	false	none	Consumption of a high fat meal just prior to dosing in the morning had no effect on the extent of absorption and a modest effect on the rate of absorption from verapamil hydrochloride extended-release capsules (PM).  The rate of absorption was not affected by whether the volunteers were supine 2 hours after night-time dosing or nonsupine for 4 hours following morning dosing.  Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		11170	none	11170	C016904
Verapamil	norverapamil	46	46	false	none	Similar results were observed with norverapamil.  		11170	none	11170	C016904
Verapamil	norverapamil	46	46	false	none	Similar results were observed with norverapamil.  		11170	none	11170	C016904
Verapamil	norverapamil	46	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		11170	none	11170	C016904
Verapamil	norverapamil	46	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		11170	none	11170	C016904
Verapamil	norverapamil	47	46	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  		11170	none	11170	C016904
Verapamil	norverapamil	47	46	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  		11170	none	11170	C016904
Verapamil	norverapamil	44	46	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		11170	none	11170	C016904
Verapamil	norverapamil	44	46	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		11170	none	11170	C016904
Verapamil	norverapamil	44	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		11170	none	11170	C016904
Verapamil	norverapamil	44	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  		11170	none	11170	C016904
Verapamil	norverapamil	45	46	false	none	When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		11170	none	11170	C016904
Verapamil	norverapamil	45	46	false	none	When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  Similar results were observed with norverapamil.  		11170	none	11170	C016904
Verapamil	norverapamil	45	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  		11170	none	11170	C016904
Verapamil	norverapamil	45	44	false	none	Administering verapamil hydrochloride extended-release capsules (PM) in the morning increased the extent of absorption of verapamil and/or decreased the metabolism to norverapamil.  When the contents of the verapamil hydrochloride extended-release capsules (PM) were administered by sprinkling onto one tablespoonful of applesauce, the rate and extent of verapamil absorption were found to be bioequivalent to the same dose when administered as an intact capsule.  		11170	none	11170	C016904
Verapamil	norverapamil	48	46	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  Racemic verapamil is released from verapamil hydrochloride extended-release capsules (PM) by diffusion following the gradual solubilization of the water soluble polymer.  		11170	none	11170	C016904
Verapamil	norverapamil	48	46	true	positive	Similar results were observed with norverapamil.  Distribution    Although some evidence of lack of dose linearity was observed for verapamil hydrochloride extended-release capsules (PM), this non-linearity was enantiomer specific, with the R enantiomer showing the greatest degree of nonlinearity.  Racemic verapamil is released from verapamil hydrochloride extended-release capsules (PM) by diffusion following the gradual solubilization of the water soluble polymer.  		11170	none	11170	C016904
Verapamil	norverapamil	63	64	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		11170	none	11170	C016904
Verapamil	norverapamil	63	64	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		11170	none	11170	C016904
Verapamil	norverapamil	63	65	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	none	11170	C016904
Verapamil	norverapamil	63	65	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	none	11170	C016904
Verapamil	norverapamil	63	63	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  		11170	none	11170	C016904
Verapamil	norverapamil	63	63	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  		11170	none	11170	C016904
Verapamil	norverapamil	71	73	false	none	In addition, in these patients there is a reduced first pass effect, and verapamil is more bioavailable.  Verapamil clearance values suggest that patients with liver dysfunction may attain therapeutic verapamil plasma concentrations with one third of the oral daily dose required for patients with normal liver function.  After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  		11170	none	11170	C016904
Verapamil	norverapamil	71	73	false	none	In addition, in these patients there is a reduced first pass effect, and verapamil is more bioavailable.  Verapamil clearance values suggest that patients with liver dysfunction may attain therapeutic verapamil plasma concentrations with one third of the oral daily dose required for patients with normal liver function.  After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  		11170	none	11170	C016904
Verapamil	norverapamil	64	64	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		11170	none	11170	C016904
Verapamil	norverapamil	64	64	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		11170	none	11170	C016904
Verapamil	norverapamil	64	65	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	none	11170	C016904
Verapamil	norverapamil	64	65	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	none	11170	C016904
Verapamil	norverapamil	64	63	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		11170	none	11170	C016904
Verapamil	norverapamil	64	63	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  		11170	none	11170	C016904
Verapamil	norverapamil	65	64	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	none	11170	C016904
Verapamil	norverapamil	65	64	true	positive	For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	none	11170	C016904
Verapamil	norverapamil	65	65	false	none	The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	none	11170	C016904
Verapamil	norverapamil	65	65	false	none	The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	none	11170	C016904
Verapamil	norverapamil	65	63	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	none	11170	C016904
Verapamil	norverapamil	65	63	true	positive	Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  For verapamil hydrochloride extended-release capsules (PM), the norverapamil R enantiomer reached steady-state plasma concentrations similar to the verapamil R enantiomer, but the norverapamil S enantiomer concentrations were approximately twice that of the verapamil S enantiomer concentrations.  The cardiovascular activity of norverapamil appears to be approximately 20% that of verapamil.  		11170	none	11170	C016904
Verapamil	norverapamil	72	73	false	none	Verapamil clearance values suggest that patients with liver dysfunction may attain therapeutic verapamil plasma concentrations with one third of the oral daily dose required for patients with normal liver function.  After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  		11170	none	11170	C016904
Verapamil	norverapamil	72	73	false	none	Verapamil clearance values suggest that patients with liver dysfunction may attain therapeutic verapamil plasma concentrations with one third of the oral daily dose required for patients with normal liver function.  After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  		11170	none	11170	C016904
Verapamil	norverapamil	73	73	false	none	After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  		11170	none	11170	C016904
Verapamil	norverapamil	73	73	false	none	After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  		11170	none	11170	C016904
Verapamil	norverapamil	74	73	false	none	After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  Geriatric Use    The pharmacokinetics of verapamil GITS were studied after 5 consecutive nights of dosing 180 mg in 30 healthy young (19 to 43 years) vs. 30 healthy elderly (65 to 80 years) male and female subjects.  		11170	none	11170	C016904
Verapamil	norverapamil	74	73	false	none	After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  Geriatric Use    The pharmacokinetics of verapamil GITS were studied after 5 consecutive nights of dosing 180 mg in 30 healthy young (19 to 43 years) vs. 30 healthy elderly (65 to 80 years) male and female subjects.  		11170	none	11170	C016904
Verapamil	norverapamil	75	73	false	none	After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  Geriatric Use    The pharmacokinetics of verapamil GITS were studied after 5 consecutive nights of dosing 180 mg in 30 healthy young (19 to 43 years) vs. 30 healthy elderly (65 to 80 years) male and female subjects.  Older subjects had significantly higher mean verapamil Cmax, Cmin and AUC(0-24h) compared to younger subjects.  		11170	none	11170	C016904
Verapamil	norverapamil	75	73	false	none	After 4 weeks of oral dosing of immediate-release verapamil (120 mg q.i.d.), verapamil and norverapamil levels were noted in the cerebrospinal fluid with estimated partition coefficient of 0.06 for verapamil and 0.04 for norverapamil.  Geriatric Use    The pharmacokinetics of verapamil GITS were studied after 5 consecutive nights of dosing 180 mg in 30 healthy young (19 to 43 years) vs. 30 healthy elderly (65 to 80 years) male and female subjects.  Older subjects had significantly higher mean verapamil Cmax, Cmin and AUC(0-24h) compared to younger subjects.  		11170	none	11170	C016904
Verapamil	p450	59	61	false	none	Metabolism and Excretion    Orally administered verapamil undergoes extensive metabolism in the liver.  Verapamil is metabolized by O-demethylation (25%) and N-dealkylation (40%), and is subject to pre-systemic hepatic metabolism with elimination of up to 80% of the dose.  The metabolism is mediated by hepatic cytochrome P450, and animal studies have implied that the mono-oxygenase is the specific isoenzyme of the P450 family.  		11170	none	11170	none
Verapamil	p450	59	61	false	none	Metabolism and Excretion    Orally administered verapamil undergoes extensive metabolism in the liver.  Verapamil is metabolized by O-demethylation (25%) and N-dealkylation (40%), and is subject to pre-systemic hepatic metabolism with elimination of up to 80% of the dose.  The metabolism is mediated by hepatic cytochrome P450, and animal studies have implied that the mono-oxygenase is the specific isoenzyme of the P450 family.  		11170	none	11170	none
Verapamil	p450	63	61	false	none	The metabolism is mediated by hepatic cytochrome P450, and animal studies have implied that the mono-oxygenase is the specific isoenzyme of the P450 family.  Thirteen metabolites have been identified in urine.  Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  		11170	none	11170	none
Verapamil	p450	63	61	false	none	The metabolism is mediated by hepatic cytochrome P450, and animal studies have implied that the mono-oxygenase is the specific isoenzyme of the P450 family.  Thirteen metabolites have been identified in urine.  Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  		11170	none	11170	none
Verapamil	p450	60	61	false	none	Verapamil is metabolized by O-demethylation (25%) and N-dealkylation (40%), and is subject to pre-systemic hepatic metabolism with elimination of up to 80% of the dose.  The metabolism is mediated by hepatic cytochrome P450, and animal studies have implied that the mono-oxygenase is the specific isoenzyme of the P450 family.  		11170	none	11170	none
Verapamil	p450	60	61	false	none	Verapamil is metabolized by O-demethylation (25%) and N-dealkylation (40%), and is subject to pre-systemic hepatic metabolism with elimination of up to 80% of the dose.  The metabolism is mediated by hepatic cytochrome P450, and animal studies have implied that the mono-oxygenase is the specific isoenzyme of the P450 family.  		11170	none	11170	none
norverapamil	p450	63	61	false	none	The metabolism is mediated by hepatic cytochrome P450, and animal studies have implied that the mono-oxygenase is the specific isoenzyme of the P450 family.  Thirteen metabolites have been identified in urine.  Norverapamil enantiomers can reach steady-state plasma concentrations approximately equal to those of the enantiomers of the parent drug.  		none	none	C016904	none
